Alterity Therapeutics (ATHE) Price & Analysis

Compare

300 Followers

ATHE Stock Chart & Stats

$3.55

-$0.16(-4.23%)

At close: Jan 08 4:00 PM EST

$3.55

-$0.16(-4.23%)

Day’s Range― - ―

52-Week Range$2.52 - $7.00

Previous CloseN/A

Volume131.33K

Average Volume (3M)13.05K

Market Cap

$53.05M

Enterprise Value$43.12M

Total Cash (Recent Filing)$40.66M

Total Debt (Recent Filing)$155.46K

Price to Earnings (P/E)―

Beta1.15

Next Earnings

Feb 26, 2026

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding18,125,694

10 Day Avg. Volume16,981

30 Day Avg. Volume13,055

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)1.56

Price to Sales (P/S)12.18

P/FCF Ratio-5.79

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue7.93

Enterprise Value/Gross Profit8.12

Enterprise Value/Ebitda-2.95

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 2 data showed ATH434 produced a clinically meaningful reduction in disease severity on the UMSARS scale and stabilized orthostatic hypotension versus decline on placebo, supporting potential symptomatic benefit in multiple system atrophy.

Safety And Development RiskATH434 was well tolerated in the study with no treatment-related serious adverse events reported, which may reduce safety concerns ahead of later-stage trials.

Target Engagement (neuroimaging)Neuroimaging analyses demonstrated reduced iron accumulation in the globus pallidus and other affected brain regions, providing mechanistic evidence that ATH434 engages its intended target.

Bears Say

Alterity Therapeutics News

Alterity Therapeutics provides corporate update

Alterity Therapeutics (ATHE) released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the...

4d ago

ATHE

Alterity Therapeutics highlights key 2026 objectives

Alterity Therapeutics (ATHE) issued a letter to shareholders, which read in part, “Our goal for 2025 was the...

13d ago

ATHE

Alterity Therapeutics initiated with a Speculative Buy at Canaccord

Canaccord initiated coverage of Alterity Therapeutics (ATHE) with a Speculative Buy rating and $A1.6c price target Alterity is...

2M ago

ATHE

Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says

14:00 EST Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says Published first on TheFly –...

2M ago

ATHE

Alterity CEO says to meet with FDA, move forward with Phase 3 study

14:00 EST Alterity CEO says to meet with FDA, move forward with Phase 3 study Published first on...

2M ago

ATHE

Alterity ‘really emerging’ as U.S. company, CEO tells The Fly

14:00 EST Alterity ‘really emerging’ as U.S. company, CEO tells The Fly Published first on TheFly – the...

2M ago

ATHE

Stamler says Alterity treating neurodegeneration in ‘way no one else is doing’

14:00 EST Stamler says Alterity treating neurodegeneration in ‘way no one else is doing’ Published first on TheFly...

2M ago

ATHE

Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler

In an exclusive interview, Alterity Therapeutics’ (ATHE) CEO David Stamler met with The Fly to discuss the company,...

2M ago

ATHE

Alterity Therapeutics presents analyses related to OH from ATH434-201 trial

Alterity Therapeutics (ATHE) announced that analyses on the baseline characteristics related to orthostatic hypotension, OH, from the ATH434-201...

3M ago

ATHE

Alterity Therapeutics reports cash balance of A$54.46M as of September 30

“As we near the end of the calendar year, I am very proud of all we have accomplished...

3M ago

ATHE

Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds

The latest announcement is out from Alterity Therapeutics ( ($ATHE) ). On October 14, 2025, Alterity Therapeutics Limited...

4M ago

ATHE

Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Alterity Therapeutics and keeping the price target...

4M ago

ATHE

Alterity Therapeutics Reports Positive ATH434 Phase 2 Trial Results at 2025 MDS Congress

Alterity Therapeutics ( ($ATHE) ) has issued an update. Alterity Therapeutics announced positive results from their ATH434 Phase...

4M ago

ATHE

Alterity Therapeutics Sets AGM and Director Nomination Dates

The latest announcement is out from Alterity Therapeutics ( ($ATHE) ). Alterity Therapeutics Limited announced that its next...

4M ago

ATHE

ATHE FAQ

What was Alterity Therapeutics Ltd’s price range in the past 12 months?

Alterity Therapeutics Ltd lowest stock price was $2.52 and its highest was $7.00 in the past 12 months.

What is Alterity Therapeutics Ltd’s market cap?

Alterity Therapeutics Ltd’s market cap is $53.05M.

When is Alterity Therapeutics Ltd’s upcoming earnings report date?

Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 23 days.

How were Alterity Therapeutics Ltd’s earnings last quarter?

Alterity Therapeutics Ltd released its earnings results on Feb 28, 2025. The company reported -$0.522 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.359.

Is Alterity Therapeutics Ltd overvalued?

According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alterity Therapeutics Ltd pay dividends?

Alterity Therapeutics Ltd does not currently pay dividends.

What is Alterity Therapeutics Ltd’s EPS estimate?

Alterity Therapeutics Ltd’s EPS estimate is -0.4.

How many shares outstanding does Alterity Therapeutics Ltd have?

Alterity Therapeutics Ltd has 18,125,694 shares outstanding.

What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?

Alterity Therapeutics Ltd reported an EPS of -$0.522 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went down -2.326%.

Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?

Currently, no hedge funds are holding shares in ATHE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Alterity Therapeutics Stock Smart Score

Underperform

News Sentiment

Very Bullish

Bullish news 100%
Bearish news 0%

Technicals

Fundamentals

Return on Equity

-42.68%

Trailing 12-Months

Asset Growth

134.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alterity Therapeutics Ltd

Alterity Therapeutics (ATHE) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly in the realm of protein misfolding disorders. The company operates primarily in the healthcare sector, leveraging its proprietary drug development platform to create novel treatments aimed at addressing unmet medical needs in conditions such as Alzheimer's disease and Parkinson's disease. Alterity's core pipeline includes drug candidates that target specific molecular mechanisms involved in these disorders, with the goal of improving patient outcomes and quality of life.